Prostate Cancer

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA ODAC voted for the use of capivasertib plus abiraterone in PTEN-deficient mHSPC.

Capivasertib plus abiraterone produced superior efficacy outcomes vs abiraterone alone in PTEN-deficient mHSPC.

The April 30, 2026, FDA ODAC meeting will focus on data from CAPItello-281 for capivasertib plus abiraterone in PTEN-deficient mHSPC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Rana R. McKay, MD, discusses findings from the phase 4 OPTYX trial of real-world relugolix in advanced prostate cancer.

Rana R. McKay, MD, discusses, the study design and baseline patient characteristics of the OPTYX trial of relugolix in advanced prostate cancer

Rana R. McKay, MD, discussed the rationale behind the phase 4 OPTYX trial evaluating relugolix in advanced prostate cancer.

David R. Wise, MD, PhD, discusses data from a phase 1b study of pasritamig plus docetaxel in mCRPC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Rana R. McKay, MD, discusses data from the phase 4 OPTYX study of real-world relugolix in prostate cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

David Morris, MD, FACS, and Alan H. Bryce, MD, discuss the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

Isaac Y. Kim, MD, PhD, MBA, and Anthony V. D'Amico, MD, PhD, discuss radiotherapy, surgery, and emerging strategies in mHSPC.

Lutetium-177 rosopatamab tetraxetan plus SOC therapies was safe and tolerable in patients with PSMA-positive mCRPC.

Neha Vapiwala, MD, FACR, FASTRO, FASCO, unpacks notable updates from ASCO GU and discusses a trend toward individualized therapy in prostate cancer.

The EC approved an indication extension for niraparib and abiraterone acetate dual-action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.